OverviewSuggest Edit

Foghorn Therapeutics is a developer of gene therapies for hematologic cancers and solid tumors. Through its Gene Traffic Control platform, the company studies, identifies, and validates potential drug targets within the chromatin regulatory system.

TypePublic
Founded2016
HQCambridge, MA, US
Websitefoghorntx.com

Latest Updates

Employees (est.) (Aug 2020)85
Job Openings19
Revenue (FY, 2020)$430 K
Share Price (Nov 2021)$14.6(+6%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Foghorn Therapeutics

Adrian Gottschalk

Adrian Gottschalk

Director, President & CEO
Samuel Agresta

Samuel Agresta

Chief Medical Officer
Fanny Cavalié

Fanny Cavalié

SVP, Business & Operations
Steve Bellon

Steve Bellon

SVP, Drug Discovery
Carlos Costa

Carlos Costa

SVP, People & Organization
Jacqueline Cinicola

Jacqueline Cinicola

VP, Regulatory Affairs
Show more

Foghorn Therapeutics Office Locations

Foghorn Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
NE47, 500 Technology Square #700
Cambridge, MA, US
100 Binney St #610
Show all (2)

Foghorn Therapeutics Financials and Metrics

Foghorn Therapeutics Revenue

Foghorn Therapeutics's revenue was reported to be $430 k in FY, 2020
USD

Revenue (Q1, 2021)

286.0k

Net income (Q1, 2021)

(23.0m)

EBIT (Q1, 2021)

(23.1m)

Market capitalization (12-Nov-2021)

513.3m

Closing stock price (12-Nov-2021)

14.6

Cash (31-Mar-2021)

66.4m

EV

529.2m
Foghorn Therapeutics's current market capitalization is $513.3 m.
Annual
USDFY, 2018FY, 2019FY, 2020

Revenue

430.0k

General and administrative expense

4.8m6.7m11.2m

R&D expense

21.2m44.4m57.7m

Operating expense total

26.0m51.1m69.0m
Half Year
USDH1, 2019H1, 2020

General and administrative expense

3.2m4.1m

R&D expense

19.6m25.1m

Operating expense total

22.8m29.3m

EBIT

(22.8m)(29.3m)
Quarterly
USDQ3, 2020Q1, 2021

Revenue

179.0k286.0k

General and administrative expense

2.6m4.7m

R&D expense

16.1m18.7m

Operating expense total

18.7m23.4m
Annual
USDFY, 2018FY, 2019FY, 2020

Cash

40.0m15.0m92.8m

Prepaid Expenses

4.9m

Current Assets

40.4m16.9m190.7m

PP&E

2.1m2.7m19.5m
Quarterly
USDQ2, 2020Q3, 2020Q1, 2021

Cash

36.6m74.6m66.4m

Prepaid Expenses

2.6m4.4m

Current Assets

39.0m77.8m165.3m

PP&E

8.2m16.8m
Annual
USDFY, 2018FY, 2019FY, 2020

Net Income

(26.3m)(51.1m)(68.8m)

Depreciation and Amortization

379.0k693.0k1.3m

Accounts Payable

1.3m1.2m474.0k

Cash From Operating Activities

(22.6m)(46.3m)(31.3m)
Quarterly
USDQ2, 2019Q2, 2020Q3, 2020Q1, 2021

Net Income

(22.7m)(29.7m)(48.0m)(23.0m)

Depreciation and Amortization

290.0k509.0k764.0k

Accounts Payable

1.1m(285.0k)(374.0k)(754.0k)

Cash From Operating Activities

(20.9m)(23.4m)(20.6m)(23.1m)
USDFY, 2018

Financial Leverage

-1.1 x
Show all financial metrics

Foghorn Therapeutics Operating Metrics

Q2, 2020

Discovery Stage Products

3

IND-Enabling Stage Products

2
Show all operating metrics

Foghorn Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Foghorn Securities Corporation

Foghorn Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

96/100

SecurityScorecard logo

Foghorn Therapeutics Online and Social Media Presence

Embed Graph

Foghorn Therapeutics News and Updates

Foghorn Therapeutics Provides Third Quarter 2021 Corporate Update

-- First patient dosed in phase 1 clinical trial of FHD-609, a potent and selective heterobifunctional protein degrader of BRD9, initially being developed for the treatment of synovial sarcoma

Foghorn Therapeutics Announces Presentation at Upcoming 4th Annual Targeted Protein Degradation Summit

David Millan, PhD, VP of Chemistry, to present overview of company’s proprietary protein degrader platform and its clinical stage asset, FHD-609, a potent and selective heterobifunctional degrader of BRD9 David Millan, PhD, VP of Chemistry, to present overview of company’s proprietary protein degrad…

Foghorn Therapeutics to Participate in Two Upcoming Virtual Investor Conferences

CAMBRIDGE, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a clinical stage biotechnology company pioneering a new class of medicines that modulate gene expression through selectively targeting the chromatin regulatory system, today announced that Foghorn manage…

Foghorn Therapeutics Announces First Patient Dosed in First-in-Human Clinical Trial of FHD-609

FHD-609 is a first-in-class, highly potent and selective protein degrader of BRD9

Foghorn Therapeutics Provides Second Quarter 2021 Corporate Update

-- First Patients Dosed in Phase 1 Clinical Trials of FHD-286, an Inhibitor of BRG1/BRM, in Metastatic Uveal Melanoma and Relapsed or Refractory Acute Myeloid Leukemia (AML)

Foghorn Therapeutics to Participate at the 2021 Wedbush PacGrow Healthcare Virtual Conference

CAMBRIDGE, Mass., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system, today announced that Steven Bellon, Ph.…
Show more

Foghorn Therapeutics Blogs

Foghorn® Therapeutics Announces Collaboration with Merck to Discover and Develop Novel Oncology Therapeutics Against Transcription Factor Target

The post Foghorn® Therapeutics Announces Collaboration with Merck to Discover and Develop Novel Oncology Therapeutics Against Transcription Factor Target appeared first on Foghorn Therapeutics.

Foghorn® Therapeutics Appoints Scott Biller, Ph.D., to Board of Directors

New Director to Bring 30+ Years of Drug Development Expertise as Foghorn Prepares to Enter the Clinic The post Foghorn® Therapeutics Appoints Scott Biller, Ph.D., to Board of Directors appeared first on Foghorn Therapeutics.

Foghorn® Therapeutics Expands Leadership Team with Two C-Suite Appointments

Samuel Agresta appointed Chief Medical Officer; Allan Reine to serve as Chief Financial Officer The post Foghorn® Therapeutics Expands Leadership Team with Two C-Suite Appointments appeared first on Foghorn Therapeutics.

Foghorn Therapeutics Frequently Asked Questions

  • When was Foghorn Therapeutics founded?

    Foghorn Therapeutics was founded in 2016.

  • Who are Foghorn Therapeutics key executives?

    Foghorn Therapeutics's key executives are Adrian Gottschalk, Samuel Agresta and Fanny Cavalié.

  • How many employees does Foghorn Therapeutics have?

    Foghorn Therapeutics has 85 employees.

  • What is Foghorn Therapeutics revenue?

    Latest Foghorn Therapeutics annual revenue is $430 k.

  • What is Foghorn Therapeutics revenue per employee?

    Latest Foghorn Therapeutics revenue per employee is $5.1 k.

  • Who are Foghorn Therapeutics competitors?

    Competitors of Foghorn Therapeutics include Arvinas, Nurix and Ultivue.

  • Where is Foghorn Therapeutics headquarters?

    Foghorn Therapeutics headquarters is located at NE47, 500 Technology Square #700, Cambridge.

  • Where are Foghorn Therapeutics offices?

    Foghorn Therapeutics has an office in Cambridge.

  • How many offices does Foghorn Therapeutics have?

    Foghorn Therapeutics has 2 offices.